Panel Pushes For “Pragmatic” Post-Marketing Study, Head-To-Head Comparison For Forest’s Aclidinium

FDA’s Pulmonary-Allergy Drugs Advisory Committee suggests including endpoints that will help determine the value added by the COPD drug. Forest Labs says it is ready to discuss post-marketing options with FDA.